All News

Experts discuss key challenges in testing and diagnosing a patient with chronic kidney disease, especially for those who are asymptomatic. In addition, they highlight new screening approaches to accurately identify these patients.

The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.

Your daily dose of the clinical news you may have missed.

The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.

A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.

Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.

IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.

Your daily dose of the clinical news you may have missed.

At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.

Experts discuss the emerging landscape of multicancer early detection testing through liquid biopsy, highlighting its potential to revolutionize cancer screening.

Ailiani, director of MedStar Georgetown Headache Center, focuses on optimizing treatment with CGRP inhibitors and where research on PACAP-targeting agents stands now.

In postmenopausal women with HR+ breast cancer who had obesity, recurrence of breast cancer while on aromatase inhibitor therapy was 18%, report investigators.

President of the Alabama Obesity Society, Dr Jonathan Parker, provides an in-depth overview of the association between obesity and hypertension.

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

Your daily dose of the clinical news you may have missed.

Reasons for not getting a COVID-19 booster ranged from worry about taking time off to believing it won't add any additional protection from infection.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.